Date: 2016-03-15
Type of
information: Initiation of development program
phase: 2
Announcement: initiation of development program
Company: ProMetic Life Sciences (Canada)
Product: PBI-4050
Action
mechanism:
- antifibrotic agent. PBI-4050 is an orally active lead drug candidate with excellent safety and efficacy profiles confirmed in several in vivo experiments targeting fibrosis.
Disease: scleroderma
Therapeutic
area: Autoimmune diseases - Rheumatic diseases
Country:
Trial
details:
Latest
news:
- • On March 15, 2016, ProMetic Life Sciences announced that it will be initiating a double-blind, placebo-controlled phase 2 clinical trial in patients suffering from scleroderma. There is no cure for scleroderma, a chronic disorder characterized by an overproduction of collagen and abnormal growth of connective tissue. This collagen accumulation causes scarring (fibrosis) of the skin, and in the case of systemic scleroderma, also affects internal organs such as the lungs, the kidneys and gastrointestinal system. “PBI-4050 has been shown to significantly reduce fibrosis in several of the key organs in various preclinical models, irrespective of the cause of the injuries or whether acute or chronic in nature”, stated Dr. Lyne Gagnon, VP of R&D preclinical at ProMetic. “The most recent results have shown that even in mice genetically programmed to develop scleroderma, PBI-4050 prevented the over production of collagen and the formation of fibrotic scarring”, added Dr. Gagnon.
Is
general: Yes
